Assembly Biosciences (ASMB) Operating Expenses (2010 - 2026)

Assembly Biosciences' Operating Expenses history runs 17 years deep, the most recent figure standing at $19.6 million for Q1 2026.

• On a quarterly basis, Operating Expenses rose 1.15% year-over-year to $19.6 million in Q1 2026; TTM through Mar 2026 was $84.6 million, a 10.23% increase from a year earlier, with the FY2025 full-year figure at $84.4 million, up 14.18% from the prior year.
• Operating Expenses retreated to $19.6 million in Q1 2026 per ASMB's latest filing, from $22.7 million in the prior quarter.
• Across five years, Operating Expenses topped out at $24.6 million in Q2 2022 and bottomed at $15.0 million in Q3 2023.
• The 5-year median for Operating Expenses is $19.7 million (2023), against an average of $20.2 million.
• Across the five-year window, Operating Expenses plunged 63.46% in 2022 and grew 21.75% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $23.0 million in 2022, then fell by 14.2% to $19.7 million in 2023, then declined by 4.18% to $18.9 million in 2024, then advanced by 20.02% to $22.7 million in 2025, then slipped by 13.62% to $19.6 million in 2026.
• Per Business Quant, the three latest ASMB Operating Expenses figures stand at $19.6 million (Q1 2026), $22.7 million (Q4 2025), and $21.7 million (Q3 2025).